2021. RFLSP.Russian.Finnish.Life.Science.Industry.EN

More documents

Recommendations

Info

1.1.2 Commercial segment of the Russian pharmaceutical marketThe results of the pharmaceutical market in 2020 were largely influenced by consumerbehavior in the context of the Covid-19 pandemic. With the emergence of news about themethods of treating coronavirus infection, there was an increased demand for one or anothergroup of drugs. This led to an increase in sales, and at times a shortage, when manufacturerswere not ready to meet the demand in full.According to DSM Group, at the end of 2020, the market growth in the commercial segmentin rubles was 11%, while in physical terms it remained in the negative zone – -2%. Thus, theretail segment sold about 5.0 billion packages of drugs worth 1,128 billion rubles (in retailprices).Dynamics of the commercial drugsmarket, RUB blnDynamics of the commercial drugsmarket, mln packages896 (+6%) (+5%) (+3%)(+11%)4 896(+2%)(+4%)(-2%)(-2%)2016 2017 2018 2019 2020Source: DSM Group2016 2017 2018 2019 2020Source: DSM GroupThe consumption of drugs at the expense of the population's own funds remains one of themain elements of the healthcare system drug supply: about 64% in monetary terms andalmost 85% in packages. Hence the high requirements for pharmacies who in this case act asa sales channel. At the beginning of 2020, pharmacies were getting ready to sell labeledmedicines from July 1, 2020. But the spread of the new coronavirus infection created anadditional challenge: shortages of certain pharmacy products.In 2020, there were no seasonal or other common trends inherent in the pharmacy market.Antivirals and antibiotics were in greatest demand during the pandemic. Moreover, even insummer, sales of these categories of drugs were significantly higher than in previous years.The structure of drug consumption in 2020 was influenced by such macroeconomic factors asthe crisis caused by the pandemic, the lockdown, the decline of real disposable income (-3.5%according to the Federal State Statistics Service), the change in household spending in favor16RUSSIAN-FINNISH LIFE SCIENCE INDUSTRYResearch and export directory
of mandatory payments and savings, the overall inflation rate (4.91%) and even higher onefor food products (6.7%).The dynamics in the commercial segment of pharmaceuticals in 2020 was difficult to predict:all previously established trends have changed. In March 2020, drug demand exploded andthe pharmaceutical market experienced one of the most significant sales gains in the pastfew years. With the spreading coronavirus infection and the deteriorating economicsituation, consumers began to massively buy drugs, apprehending a rise in prices in thecontext of a weakening ruble and a shortage of necessary drugs due to restrictive measures.Subsequently, the sales dynamics were weak and even negative in some months. Only inDecember, the market returned to the growth rates that were in January-February 2020, i.e.before the events related to the pandemic. Since April, sales growth has been mainly drivenby anti-covid drugs. Their list varied, but due to the high demand for them, the marketshowed positive dynamics in rubles (+10.6%) and decreased only in units – by 2.3%. In 2020,5,002 million packages of drugs worth 1,128 billion rubles (in retail prices) were sold throughthe pharmacy network.Pharmacy sales of parapharmaceutical products, as it traditionally happens during crisisperiods, grew more slowly than sales of drugs: the volume of this segment grew by 6.7% andamounted to 279 billion rubles. The growth was mainly noted due to dietary supplements (inparticular vitamins and immunity boosters), personal protective equipment (masks),sanitizers, medical appliances. These types of goods are indirectly but related to preventingthe spread of Covid-19.RUSSIAN-FINNISH LIFE SCIENCE INDUSTRYResearch and export directory17
Page 2 and 3: This publication was developed in t
Page 4 and 5: 1.5 Events ........................
Page 6 and 7: 2.42 PHARM-HOLDING ................
Page 8 and 9: 1 PART 1: MARKET RESEARCH1.1 Indust
Page 10 and 11: The Russian pharmaceutical market i
Page 12 and 13: Imported/localized drugs sales rati
Page 14 and 15: In 2020, the share of original drug
Page 18 and 19: 1.1.3 Drug reimbursement segmentAcc
Page 20 and 21: 1.1.4 Segment of purchases of drugs
Page 22 and 23: 1.1.5 Dietary supplements segmentAc
Page 24 and 25: The development of the innovative d
Page 26 and 27: Dynamics of pharmaceutical products
Page 28 and 29: § the term of the SPIC has been ex
Page 30 and 31: The Pharma-2030 Strategy elaboratio
Page 32 and 33: presence of viral RNA and antibodie
Page 34 and 35: § training system in the field of
Page 36 and 37: counter external risks (for example
Page 38 and 39: 1.3.2 The Pavlov First Saint Peters
Page 40 and 41: 1.3.3 North-Western State Medical U
Page 42 and 43: 1.3.4 Military Medical Academy name
Page 44 and 45: 1.3.6 Saint-Petersburg State Instit
Page 46 and 47: 1.3.7 Peter the Great St. Petersbur
Page 48 and 49: 1.3.9 Saint-Petersburg Medico-Socia
Page 50 and 51: 1.4.2 Almazov National Medical Rese
Page 52 and 53: 1.4.4 Institute of Cytology RASInst
Page 54 and 55: 1.4.6 Kashkin Research Institute of
Page 56 and 57: 1.4.8 Research Institute of Hygiene
Page 58 and 59: 1.4.10 Saint-Petersburg Pasteur Ins
Page 60 and 61: Contact informationBekhtereva Str.,
Page 62 and 63: The Institute has Influenza and ARD
Page 64 and 65: 1.4.14 V. M. Gorbatov Federal Resea
Page 66 and 67:
1.5 Events1.5.1 Events calendarDate
Page 68 and 69:
1.5.2.2 Nordic Life Science DaysNor
Page 70 and 71:
1.5.2.4 HealthBIOThe HealthBIO even
Page 72 and 73:
1.5.2.6 BioJapanBioJapan has played
Page 74 and 75:
1.5.2.8 CPhI WorldwideCPhI is an es
Page 76 and 77:
1.5.2.10 INTERPHEX Japan 2021INTERP
Page 78 and 79:
1.5.3.2 IPhEB RussiaIPhEB Russia is
Page 80 and 81:
1.6 Clusters and associations1.6.1
Page 82 and 83:
1.6.3 Cluster of medical, environme
Page 84 and 85:
1.7 Cases and success stories1.7.1
Page 86 and 87:
1.8 Information sources1.8.1 Strate
Page 88 and 89:
§ DSM Group. Analytical report “
Page 90 and 91:
2.2 ALKOR BIOCompany profileThe St.
Page 92 and 93:
2.4 AMBERCompany profileAmber Group
Page 94 and 95:
2.6 AVENACompany profileAvena compa
Page 96 and 97:
2.8 BELKOZINCompany profileBelkozin
Page 98 and 99:
2.10 BIOCADCompany profileBiocad is
Page 100 and 101:
2.12 BIOPHARMOSCompany profileBioPh
Page 102 and 103:
2.14 BIOTECHCompany profileBiotech
Page 104 and 105:
2.16 CYTOMEDCompany profileCytomed
Page 106 and 107:
2.18 EKVUSCompany profile“Ekvus
Page 108 and 109:
2.20 FARMAKOGENCompany profileFarma
Page 110 and 111:
2.22 FRAMEBIOTEKCompany profileFram
Page 112 and 113:
2.24 GEROPHARMCompany profileGeroph
Page 114 and 115:
2.26 GROTEXCompany profileSolopharm
Page 116 and 117:
2.28 HARMSCompany profileHistory of
Page 118 and 119:
2.30 LEKKERCompany profileThe histo
Page 120 and 121:
2.32 NEPHRONCompany profileResearch
Page 122 and 123:
2.34 NIKACompany profileNika Factor
Page 124 and 125:
2.36 PHARM. ASSOCIATION NAMED FOR P
Page 126 and 127:
2.38 PHARMA VAMCompany profilePharm
Page 128 and 129:
2.40 PHARMAKOR PRODUCTIONCompany pr
Page 130 and 131:
2.42 PHARM-HOLDINGCompany profilePh
Page 132 and 133:
2.44 PHARMSYNTHEZCompany profilePha
Page 134 and 135:
2.46 PPDPCompany profileEnterprise
Page 136 and 137:
2.48 RESEARCH INSTITUTE OF INNOVATI
Page 138 and 139:
2.50 SEVERNAIA ZVEZDACompany profil
Page 140 and 141:
2.52 VITAL DEVELOPMENT CORPORATIONC
Page 142 and 143:
For notes142RUSSIAN-FINNISH LIFE SC
Page 144:
144RUSSIAN-FINNISH LIFE SCIENCE IND
show all

2021. RFLSP.Russian.Finnish.Life.Science.Industry.EN

Create successful ePaper yourself

Delete template?

Save as template?